CV Therapeutics
CV Therapeutics, Inc. is a research-based biopharmaceutical company that manufactures drugs for the treatment of cardiovascular diseases
Business Model:
Revenue: $0
Employees: 201-500
Rankings
Industries / Tags:
Detailed CV Therapeutics Information
CV Therapeutics was acquired by
Gilead Sciences.
The acquisition happend on 2009-04-17.
Details of the transaction were not public
Acquirer
Geographic Data
Address:
City: Palo Alto
State: California
Zip:
Country: United States
Financial Info
Stage:
undisclosed
Raised Last:
$0
Raised Total:$0
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/1991 | Funding Round | 1 | - |
Frazier Healthcare Partners Frazier Healthcare Partners |
1/1991 | Funding Round | 1 | - |
Frazier Healthcare Partners Frazier Healthcare Partners |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
